MDMA-Assisted Therapy in Canada

MDMA-assisted therapy in Canada is legal medicine when accessed through the right regulatory pathway — and like psilocybin, that pathway has one door: Health Canada's Special Access Program (SAP). The January 5, 2022 SAP amendment added MDMA (alongside psilocybin) to practitioner-initiated SAP eligibility for patients with serious or life-threatening conditions where conventional treatments have failed. MDMA is a Schedule I controlled substance under the CDSA (Controlled Drugs and Substances Act) — more restrictive than psilocybin's Schedule III status — and has no Health Canada approved indication. The clinical evidence base is concentrated in PTSD and is the strongest published evidence for any psychedelic-assisted therapy: Mitchell et al. 2021 Nature Medicine MAPP1 Phase 3 (effect size d≈0.91) and Mitchell et al. 2023 Nature Medicine MAPP2 Phase 3 (effect size d≈1.0) demonstrated substantial PTSD-specific benefit. The regulatory landscape has been turbulent: in August 2024 the FDA declined Lykos Therapeutics' approval for MDMA-AT for PTSD via a Complete Response Letter; Lykos has been pursuing additional studies. Canadian SAP-pathway access continues. Approximately 41 MDMA SAP approvals had been granted as of February 2024 — substantially fewer than the ~176 psilocybin approvals over the same period. ATMA CENA supports preparation and integration for SAP-pathway MDMA-AT patients via coordinated care in coordination with the patient's prescribing physician. This hub article walks through what MDMA-AT is, who the strongest-evidenced indication targets are (PTSD foundationally), how the Canadian SAP pathway works for MDMA specifically, and where ATMA CENA fits.

Key takeaways

• MDMA is Schedule I under the CDSA (more restrictive than psilocybin's Schedule III). No Health Canada approved indication. Clinical access is via the Special Access Program (SAP) only since January 5, 2022.
• SAP is physician/NP-initiated — patients cannot apply directly. The prescribing practitioner documents conventional treatment failures and submits a case-specific request.
• Canadian SAP statistics: ~41 MDMA approvals as of February 2024 — substantially fewer than psilocybin's ~176 over the same period. Approval rates declined further in 2025.
• Strongest evidence: PTSD. Mitchell 2021 MAPP1 (Nat Med) and Mitchell 2023 MAPP2 (Nat Med) Phase 3 trials demonstrated d≈0.91 and d≈1.0 effect sizes — substantially larger than published ketamine PTSD effect sizes.
• Lykos Therapeutics (formerly MAPS PBC) is the primary developer. FDA declined approval in August 2024 via Complete Response Letter; Lykos pursuing additional studies. Canadian regulatory status remains SAP-only.
• Three-session standard protocol: each session ~8 hours; typically 2 therapists; 80 mg initial dose with optional 40 mg booster (Mitchell protocol).
• MDMA is not a classic psychedelic in the 5-HT2A agonism sense — it is a serotonin and norepinephrine releaser with oxytocin-mediated emotional opening; the experience is distinct from psilocybin or LSD.
• Veterans Affairs Canada considers MDMA-AT case-by-case for service-related PTSD when SAP-approved — particularly relevant given veteran/first-responder PTSD prevalence.
• Quebec public funding precedent for psychedelic therapy (Farzin/Stephan December 2022) was psilocybin-specific; Quebec has not extended the precedent to MDMA at this time.
• ATMA CENA supports preparation and integration for SAP-pathway MDMA-AT patients via the coordinated care model. The medical SAP application is initiated by the patient's prescribing physician.

What is MDMA-assisted therapy?

MDMA-assisted therapy is a structured clinical model that pairs three high-dose MDMA sessions (typically 80–120 mg with optional booster) over 12 weeks with structured preparation and integration psychotherapy around each. The dosing sessions are 6–8 hours in a clinical setting with two trained therapists present (the standard two-therapist model in MAPS-supported protocols), and they are bookended by preparation sessions before and integration sessions after each dosing day.

The therapeutic mechanism is hypothesized to involve serotonin and norepinephrine release, oxytocin-mediated emotional openness, reduced fear-of-attachment and prefrontal-amygdala reorganization that allows traumatic content to be processed without overwhelm. MDMA's experiential profile is distinct from classic 5-HT2A psychedelics like psilocybin: less perceptual disturbance, more emotional connection and relational warmth, less ego dissolution.

For the modality deep dive, see What Is MDMA-Assisted Therapy?.

How MDMA-AT differs from psilocybin or ketamine therapy

For the cross-treatment comparisons, see MDMA vs Ketamine for PTSD (Wave 2 sibling) and Psilocybin vs Ketamine Therapy.

The Canadian regulatory framework — three layers

Federal — CDSA Schedule I

MDMA is controlled under Schedule I of the Controlled Drugs and Substances Act (CDSA) — the most restrictive scheduling in Canadian drug law. Schedule I includes substances with no recognized medical use under Canadian law absent specific authorization, with criminal penalties for unauthorized possession, trafficking, and production.

The practical implications for therapeutic access:

• Prescription-required where authorized — but no approved Canadian indication closes the standard prescribing pathway
• SAP authorization is the only legal therapeutic route
• Recreational possession is illegal with serious criminal penalties

The federal framework is described at Canada.ca — MDMA / Ecstasy.

Health Canada — SAP, the only legal access pathway

Health Canada's Special Access Program is the only legal pathway. The two key dates:

• August 2020: TheraPsil-led advocacy secured Section 56(1) exemptions for psilocybin (not yet MDMA) — established proof-of-concept for the regulatory framework that would expand.
• January 5, 2022: Health Canada amended the Food and Drug Regulations to allow practitioner-initiated SAP requests for MDMA and psilocybin for serious or life-threatening conditions where conventional treatments have failed, are unsuitable, or are unavailable. See the Health Canada SAP psychedelic-assisted psychotherapy notice.

The SAP pathway requires:

• A licensed physician or nurse practitioner submits a case-specific MDMA SAP request
• Patient documentation of failed conventional treatments (most commonly: failed first-line PTSD treatments — trauma-focused CBT, prolonged exposure, EMDR, SSRIs/SNRIs)
• Clinical justification with reference to peer-reviewed evidence
• Identification of a drug source — typically Lykos-supplied MDMA via clinical-trial pathways or imported pharmaceutical-grade MDMA
• Standard SAP screening exclusions

For the SAP detail, see How to Access MDMA-Assisted Therapy in Canada.

Provincial — variable

Provincial medical regulators have not generally issued MDMA-specific policies. CPSA Alberta has issued psychedelic-assisted therapy guidance applicable to ATMA CENA's corporate clinic operations. Quebec's Bill 21 (loi 21, 2009) reserved-act psychotherapy framework applies — only physicians, psychologists, and OPQ permit holders may deliver the psychotherapy component.

What conditions is MDMA SAP-approved for?

Canadian MDMA SAP authorizations are case-specific. The dominant indication by published evidence and approved cases:

PTSD — the primary indication

This is where the Canadian and international evidence converges. Two Phase 3 trials anchor the published literature:

• Mitchell et al. 2021, Nature Medicine — MAPP1: randomized double-blind Phase 3 RCT in 90 patients with severe PTSD. Three MDMA sessions (80–120 mg with optional booster) plus structured preparation and integration psychotherapy versus inactive placebo + same psychotherapy over 12 weeks. Effect size d≈0.91 on the Clinician-Administered PTSD Scale (CAPS-5). ~67% of MDMA-AT participants no longer met PTSD diagnostic criteria at study end versus ~32% in placebo arm. (PubMed)

• Mitchell et al. 2023, Nature Medicine — MAPP2: confirmatory Phase 3 RCT in 104 patients with moderate-to-severe PTSD. Effect size d≈1.0 with similar sustained benefits at follow-up. (PubMed)

Combined, MAPP1 and MAPP2 represent the largest published RCT evidence base for any psychedelic-assisted therapy. The effect sizes are substantially larger than published ketamine PTSD effects (Bryant 2024 meta-analysis g≈0.20 bias-corrected) and exceed standard PTSD pharmacotherapy effect sizes.

Earlier supporting evidence:

• Mithoefer et al. 2010 / 2018-2019 — Phase 2 trials demonstrating safety and efficacy
• Mithoefer et al. 2019 — long-term follow-up showing durable response years post-treatment
• Sessa 2017, Sessa & Nutt 2019 — clinical reviews

For the indication-specific deep dive, see MDMA-Assisted Therapy for PTSD.

Other indications — limited evidence

Smaller signals exist for:

• Social anxiety in autistic adults (Danforth et al. 2018 — small open-label)
• Couples therapy with PTSD (Monson et al. 2020 — ARROW)
• Eating disorders — emerging research

Canadian SAP authorizations for non-PTSD indications are uncommon. The realistic 2026 SAP pathway is PTSD-focused.

How MDMA works — mechanism

MDMA is not a classic psychedelic in the 5-HT2A receptor agonism sense. The mechanism involves multiple neurotransmitter systems:

• Serotonin (5-HT) release: MDMA acts on the serotonin transporter (SERT) to release serotonin from presynaptic neurons. This produces the broad mood effects.
• Norepinephrine and dopamine release: contributes to the energizing and arousal effects.
• Oxytocin release: a distinctive mechanism implicated in the emotional-warmth, attachment-opening, and reduced-fear-of-rejection effects that make MDMA-AT clinically distinct.
• Amygdala reactivity reduction: MDMA dampens amygdala response to threat cues during the dosing window, allowing patients to engage with trauma content without becoming overwhelmed.
• Prefrontal-amygdala reorganization: emerging neuroimaging evidence suggests MDMA enhances prefrontal regulation of amygdala fear circuits in ways that translate into PTSD symptom reduction.

The clinical translation: MDMA produces emotional openness without overwhelming fear, allowing trauma-focused therapeutic work to proceed in a way that conventional pharmacotherapy or talk therapy alone may not enable.

For the mechanism deep dive, see What Is MDMA-Assisted Therapy?.

What does MDMA-AT cost in Canada?

MDMA-assisted therapy through the SAP pathway typically costs CAD $7,500–$15,000 per full treatment program — substantially higher than psilocybin or ketamine pathways. Why:

• Three dosing sessions (vs 1–2 for psilocybin): each ~8 hours with two therapists, plus preparation and integration sessions before and after each dosing day.
• Drug cost: pharmaceutical-grade MDMA supply chain is more constrained than psilocybin (Filament Health's no-charge SAP supply for psilocybin does not have an MDMA equivalent at scale).
• Total clinical-day hours: roughly 24+ hours of dosing-day time across three sessions; preparation and integration typically 8–12 sessions across the program.

For comparison: psilocybin SAP-pathway typically CAD $2,500–$6,500; ATMA CENA KAT pricing tiers CAD $1,530–$6,930 for ketamine. MDMA-AT's longer protocol drives the higher cost.

For the cost deep dive, see MDMA-Assisted Therapy Cost in Canada.

Insurance reality

• No Canadian provincial drug plan lists MDMA. Quebec's RAMQ public-funding precedent (Farzin/Stephan December 2022) was psilocybin-specific; Quebec has not extended to MDMA.
• Veterans Affairs Canada considers MDMA-AT case-by-case for service-related PTSD where SAP-approved. Particularly relevant for veteran PTSD pathway.
• Private insurance: drug not covered; therapy fees may be partially covered as standard psychotherapy.
• Alberta Blue Cross PAT (March 2024): covered ketamine; MDMA was framed as future potential once formally legalized.

The Lykos / MAPS context — and the August 2024 FDA decision

The primary developer of MDMA-AT for PTSD has been Lykos Therapeutics (formerly MAPS PBC, the public-benefit corporation associated with the Multidisciplinary Association for Psychedelic Studies). Lykos ran the MAPP1 and MAPP2 Phase 3 trials and submitted a New Drug Application to the FDA for MDMA-AT for PTSD in 2024.

In August 2024, the FDA issued a Complete Response Letter declining approval, citing concerns about trial design (blinding integrity given MDMA's distinctive subjective effects), allegations of clinical-site misconduct, and the need for additional studies. Lykos has indicated it will pursue additional Phase 3 trials.

The Canadian regulatory situation:

• Canadian SAP pathway access for MDMA-AT continues despite the US decision.
• A future Health Canada Notice of Compliance for MDMA-AT remains contingent on additional Phase 3 work and a successful submission. Health Canada operates independently from the FDA but typically reviews similar evidence.
• The 2024–2025 period has been one of regulatory uncertainty for the field globally.

The honest 2026 framing: the Canadian SAP pathway is the only legal route for MDMA-AT in Canada, and the regulatory uncertainty around future formal approval does not change that pathway's operational reality.

The Canadian provider landscape

The Canadian MDMA-AT ecosystem is smaller than the psilocybin landscape but established:

• TheraPsil maintains a directory of trained Canadian clinicians; supports MDMA SAP applications alongside psilocybin work.
• MAPS Canada — separate organization from Lykos (US); supports Canadian research, training, and advocacy.
• Numinus / Stella — multi-site presence including SAP-pathway support.
• Roots to Thrive (Nanaimo BC) — group-based KAT model; SAP-pathway expansion to include MDMA-AT in development.
• Quebec collective — psychedelic-medicine clinicians with SAP-pathway experience.
• Specific Canadian MDMA-AT trained therapists: ~50+ Canadian clinicians have completed MAPS-affiliated MDMA-AT training over recent years; the precise number trained for SAP-pathway work in 2026 is smaller.

For Canadian veterans pursuing MDMA-AT — a meaningful subset given PTSD prevalence in service-connected populations — see MDMA-Assisted Therapy for Veterans (Wave 2 article).

Where ATMA CENA fits

ATMA CENA's role in SAP-pathway MDMA-AT work:

• The medical SAP application is initiated by the patient's prescribing physician or nurse practitioner — not ATMA CENA directly.
• ATMA CENA supports preparation and integration for SAP-authorized patients via the three-phase psychedelic-assisted therapy model. For MDMA specifically, this includes the more extensive preparation and integration appropriate to a three-session protocol.
• The coordinated care model lets the patient's existing therapist remain primary while ATMA CENA's clinical infrastructure provides the dosing-specific frame.
• ATMA CENA's training program prepares clinicians for psychedelic-assisted therapy work, including foundations applicable to MDMA-AT support. Confirm specific MDMA training scope at intake.

ATMA CENA does not initiate SAP applications for MDMA. The intake call discusses how ATMA CENA's preparation/integration model fits a SAP-pathway MDMA-AT course in coordination with the patient's prescribing physician.

Eligibility — honest framing

Most published MDMA-AT trials and Canadian SAP applications use these criteria:

Generally eligible:

• Adults 18 or older
• DSM-5 PTSD diagnosis with documented adequate trials of first-line treatments (trauma-focused CBT, prolonged exposure, EMDR; SSRIs/SNRIs at therapeutic dose for ≥6 weeks)
• Medically stable; able to provide informed consent

Absolute contraindications:

• Personal history of psychotic disorder (schizophrenia, schizoaffective, bipolar I)
• Current/recent mania or hypomania
• Uncontrolled cardiovascular disease, recent MI, severe structural heart disease, significant arrhythmia
• Pregnancy
• Severe hepatic impairment
• Concurrent MAOIs or serotonergic medications at high doses (serotonin syndrome risk)

Relative contraindications:

• Active substance use disorder (typical screening exclusion across psychedelic-assisted therapy)
• Severe personality disorder with marked instability
• Active SSRI/SNRI at high dose (typically tapered before MDMA dosing under prescriber supervision)

For more detail: How to Access MDMA-Assisted Therapy in Canada.

Frequently asked questions

Is MDMA-assisted therapy legal in Canada? Yes — when accessed through Health Canada's Special Access Program with prescriber authorization. MDMA is Schedule I under the CDSA with no Health Canada approved indication. Recreational possession remains illegal.

How does MDMA differ from "ecstasy"? MDMA is the pure pharmaceutical compound (3,4-methylenedioxymethamphetamine). Ecstasy is street-market product that may contain MDMA but is frequently adulterated with methamphetamine, caffeine, novel psychoactive substances, or other agents at variable purity. Clinical MDMA-AT uses pharmaceutical-grade MDMA only.

What's the strongest evidence for MDMA-AT? Mitchell 2021 MAPP1 (Nat Med) and Mitchell 2023 MAPP2 (Nat Med) Phase 3 RCTs in PTSD, with effect sizes d≈0.91 and d≈1.0 — the largest published psychedelic-assisted therapy RCT base for any indication.

What happened with the FDA decision? The FDA issued a Complete Response Letter in August 2024 declining Lykos Therapeutics' MDMA-AT for PTSD application, citing concerns about trial design and the need for additional studies. Lykos is pursuing additional Phase 3 trials. Canadian SAP-pathway access continues independently.

Will MDMA-AT eventually be approved in Canada? Possibly, depending on additional Phase 3 trial outcomes and future regulatory submissions to Health Canada. Approval would substantially expand access; the 2026 SAP-only landscape is a transitional regulatory moment.

How does MDMA-AT compare to ketamine for PTSD? MDMA-AT has substantially larger effect sizes in published Phase 3 trials (Mitchell d≈0.91-1.0 vs ketamine PTSD pooled g≈0.20 bias-corrected). But MDMA-AT is SAP-only and access-limited; ketamine has broader Canadian access including off-label legal pathways and VAC coverage. See MDMA vs Ketamine for PTSD and Ketamine Therapy for PTSD.

Can veterans access MDMA-AT through VAC? Veterans Affairs Canada considers MDMA-AT case-by-case for service-related PTSD where SAP-approved. For the veterans-specific pathway, see MDMA-Assisted Therapy for Veterans.

What does an MDMA-AT program look like? Three dosing sessions over ~12 weeks, each ~8 hours in clinic with two therapists; preparation sessions before each dosing day; integration sessions afterward. Total program is ~24 sessions across preparation, dosing, and integration. See What to Expect at an MDMA-Assisted Therapy Session.

How much does it cost? Roughly CAD $7,500–$15,000 per program — higher than psilocybin or ketamine because of the three-session protocol. See MDMA-Assisted Therapy Cost in Canada.

Where can I access MDMA-AT in Canada? Through SAP-authorized clinicians — TheraPsil-trained therapists, Numinus-network providers, Quebec collective providers, Roots to Thrive (Nanaimo BC, group-pathway in development), and other clinicians with SAP-pathway MDMA-AT training. ATMA CENA supports preparation and integration via coordinated care.

Can my regular therapist be involved? Yes — through the coordinated care model. Your existing therapist can remain the primary therapeutic relationship while ATMA CENA's clinical infrastructure provides the dosing-specific frame. In Quebec, Bill 21 reserved-act psychotherapy applies — your therapist must be a physician, psychologist, or OPQ permit holder.

Sources

1. ATMA CENA — coordinated care: https://psychedelic.healthcare/find-care
2. Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
3. Government of Canada — MDMA / Ecstasy: https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/mdma.html
4. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: MAPP1 Phase 3. Nat Med 27:1025–1033. https://pubmed.ncbi.nlm.nih.gov/33972795/
5. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: MAPP2 Phase 3. Nat Med 29:2773–2782. https://pubmed.ncbi.nlm.nih.gov/37709999/
6. Mithoefer MC, et al. (2018). 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for PTSD in military veterans, firefighters, and police officers: Phase 2 RCT. Lancet Psychiatry. https://pubmed.ncbi.nlm.nih.gov/29728331/
7. Mithoefer MC, et al. (2019). Phase 2 long-term follow-up. J Psychopharmacol.
8. Sessa B (2017). Why MDMA therapy for alcohol use disorder? Front Psychiatry.
9. Danforth AL, et al. (2018). MDMA-assisted therapy for social anxiety in autistic adults. Psychopharmacology.
10. Monson CM, et al. (2020). MDMA-AT for PTSD with cognitive-behavioural conjoint therapy. Eur J Psychotraumatol.
11. TheraPsil: https://therapsil.ca/
12. MAPS Canada: https://www.mapscanada.org/
13. PsyCan / Psychedelics Canada — Sharp decline in SAP approvals (September 2025): https://psychedelicscanada.org/media/
14. FDA Complete Response Letter on MDMA-AT for PTSD (August 2024) — context: https://www.psychiatrictimes.com/view/fda-releases-complete-response-letter-on-declining-mdma-assisted-therapy-for-ptsd
15. Veterans Affairs Canada — Mental Health Benefits: https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits

Related articles in this cluster

• What Is MDMA-Assisted Therapy?
• How to Access MDMA-Assisted Therapy in Canada (SAP)
• MDMA-Assisted Therapy Cost in Canada
• MDMA-Assisted Therapy for PTSD
• Psilocybin Therapy in Canada
• Ketamine Therapy in Canada
• Ketamine Therapy for PTSD
• Find care near you
• Psychedelic Therapy Training in Canada

Last updated: 2026-05-06